Skip to main content
SpringerLink
Log in

The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?

  • Chapter
  • First Online:
Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1411))

Abstract

The glutamatergic system is the primary excitatory pathway within the CNS and is responsible for cognition, memory, learning, emotion, and mood. Because of its significant importance in widespread nervous system function, it is tightly regulated through multiple mechanisms, such as glutamate recycling, microglial interactions, and inflammatory pathways. Imbalance within the glutamatergic system has been implicated in a wide range of pathological conditions including neurodegenerative conditions, neuromuscular conditions, and mood disorders including depression. Major depressive disorder (MDD) is the most common mood disorder worldwide, has a high prevalence rate, and afflicts approximately 280 million people. While there are numerous treatments for the disease, 30–40% of patients are unresponsive to treatment and deemed treatment resistant; approximately another third experience only partial improvement (World Health Organization, Depression fact sheet [Internet], 2020). Esketamine, the S-enantiomer of ketamine, was approved by the Food and Drug Administration for treatment-resistant depression (TRD) in 2019 and has offered new hope to patients. It is the first treatment targeting the glutamatergic system through a complex mechanism. Numerous studies have implicated imbalance in the glutamatergic system in depression and treatment resistance. Esketamine and ketamine principally work through inhibition of the NMDA receptor, though more recent studies have implicated numerous other mechanisms mediating the antidepressant efficacy of these agents. These mechanisms include increase in brain-derived neurotrophic factor (BDNF), activation of mammalian target of the rapamycin complex (mTORC), and reduction in inflammation. Esketamine and ketamine have been shown to decrease inflammation in numerous ways principally through reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) (Loix et al., Acta Anaesthesiol Belg 62(1):47–58, 2011; Chen et al., Psychiatry Res 269:207–11, 2018; Kopra et al., J Psychopharmacol 35(8):934–45, 2021). This anti-inflammatory effect has also been shown to be involved in the antidepressive properties of both ketamine and esketamine (Chen et al., Psychiatry Res 269:207–11, 2018; Kopra et al., J Psychopharmacol 35(8):934–45, 2021).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.

    Article  CAS  PubMed  Google Scholar 

  2. Crupi R, Marino A, Cuzzocrea S. New therapeutic strategy for mood disorders. Curr Med Chem. 2011;18(28):4284–98.

    Article  CAS  PubMed  Google Scholar 

  3. Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol. 2015;13(5):636–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. World Health Organization. Depression fact sheet [Internet]. 2020. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 17 Sep 2021.

  5. Center for Disease Control and Prevention. Suicide and self-inflicted injury. 2020. https://www.cdc.gov/nchs/fastats/suicide.htm. Accessed 18 Sep 2021.

  6. Institute of Health Metrics and Evaluation. Health data exchange. 2021. http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b. Accessed 7 Sep 2021.

  7. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry. 1965;13(6):483–94.

    Article  CAS  PubMed  Google Scholar 

  8. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry. 2000;61(1):5–12.

    CAS  PubMed  Google Scholar 

  9. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23(1):1–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cole CE, Patterson RM, Craig JB, Thomas WE, Ristine LP, Stahly M, et al. A controlled study of efficacy of iproniazid in treatment of depression. AMA Arch of Gen Psychiatry. 1959;1(5):513–8.

    Article  CAS  Google Scholar 

  11. Fisar Z, Hroudová J, Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645–56.

    CAS  PubMed  Google Scholar 

  12. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):381–6.

    Article  PubMed  Google Scholar 

  13. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70(12):1662–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Homberg JR, Molteni R, Calabrese F, Riva MA. The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev. 2014;43:35–47.

    Article  CAS  PubMed  Google Scholar 

  15. Björkholm C, Monteggia LM. BDNF—a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72–9.

    Article  PubMed  Google Scholar 

  16. Buetler L, Clarkin J, Bongar B. Guideline for the systematic treatment of the depressed patient. Oxford Scholarship Online. Oxford: Oxford University Press; 2000.

    Book  Google Scholar 

  17. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.

    Article  CAS  PubMed  Google Scholar 

  18. Gaynes B, Asher G, Gartlehner G, Hoffman V, Cokker-Schwimmer E. Definition of treatment-resistant depression in the medicare population. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018.

    Google Scholar 

  19. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984;42(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  20. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  21. Curtis DR, Watkins JC. The excitation and depression of spinal neurones by structurally related amino acids. J Neurochem. 1960;6:117–41.

    Article  CAS  PubMed  Google Scholar 

  22. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007;32(9):1888–902.

    Article  CAS  PubMed  Google Scholar 

  23. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293–303.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Drago A, Crisafulli C, Sidoti A, Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol. 2011;94(4):418–60.

    Article  CAS  PubMed  Google Scholar 

  26. Andersen JV, Markussen KH, Jakobsen E, Schousboe A, Waagepetersen HS, Rosenberg PA, et al. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology. 2021;196:108719.

    Article  CAS  PubMed  Google Scholar 

  27. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int. 2004;45(5):583–95.

    Article  CAS  PubMed  Google Scholar 

  28. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982;232(4):299–304.

    Article  CAS  PubMed  Google Scholar 

  29. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007;85(10):2059–70.

    Article  CAS  PubMed  Google Scholar 

  30. Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson's disease: the role of glial cells. J Pharmacol Sci. 2020;144(3):151–64.

    Article  CAS  PubMed  Google Scholar 

  31. Li CT, Yang KC, Lin WC. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies. Front Psych. 2019;9:767.

    Article  CAS  Google Scholar 

  32. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295–322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Crane G. Cyloserine as an antidepressant agent. Am J Psychiatry. 1959;115(11):1025–6.

    Article  CAS  PubMed  Google Scholar 

  34. Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry. 2010;68(9):785–94.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47(4):305–13.

    Article  CAS  PubMed  Google Scholar 

  36. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200.

    Article  CAS  PubMed  Google Scholar 

  37. Block W, Träber F, von Widdern O, Metten M, Schild H, Maier W, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol. 2009;12(3):415–22.

    Article  CAS  PubMed  Google Scholar 

  38. Clark DL, MacMaster FP, Brown EC, Kiss ZHT, Ramasubbu R. Rostral anterior cingulate glutamate predicts response to subcallosal deep brain stimulation for resistant depression. J Affect Disord. 2020;266:90–4.

    Article  CAS  PubMed  Google Scholar 

  39. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2007;61(2):162–6.

    Article  CAS  PubMed  Google Scholar 

  40. Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. 2019;24(7):952–64.

    Article  CAS  PubMed  Google Scholar 

  41. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33(1):88–109.

    Article  CAS  PubMed  Google Scholar 

  42. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63–77.

    Article  CAS  PubMed  Google Scholar 

  43. Mateos-Aparicio P, Rodríguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Barbon A, Popoli M, La Via L, Moraschi S, Vallini I, Tardito D, et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry. 2006;59(8):713–20.

    Article  CAS  PubMed  Google Scholar 

  45. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007;6(2):117–26.

    Article  CAS  PubMed  Google Scholar 

  46. Schoepfer R, Monyer H, Sommer B, Wisden W, Sprengel R, Kuner T, et al. Molecular biology of glutamate receptors. Prog Neurobiol. 1994;42(2):353–7.

    Article  CAS  PubMed  Google Scholar 

  47. Du J, Feng L, Yang F, Lu B. Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J Cell Biol. 2000;150(6):1423–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Lee B, Kim Y. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Yu H, Chen ZY. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin. 2011;32(1):3–11.

    Article  CAS  PubMed  Google Scholar 

  50. Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol. 2018;38(3):579–93.

    Article  PubMed  Google Scholar 

  51. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res. 2005;53(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  53. Bliss TV, Cooke SF. Long-term potentiation and long-term depression: a clinical perspective. Clinics (Sao Paulo). 2011;66(1):3–17.

    Article  PubMed  Google Scholar 

  54. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(1):70–5.

    Article  CAS  Google Scholar 

  55. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995;675(1–2):157–64.

    Article  CAS  PubMed  Google Scholar 

  56. Martinez-Turrillas R, Frechilla D, Del Río J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology. 2002;43(8):1230–7.

    Article  CAS  PubMed  Google Scholar 

  57. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011;224(1):107–11.

    Article  CAS  PubMed  Google Scholar 

  58. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29(7):419–23.

    Article  CAS  PubMed  Google Scholar 

  59. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci. 2002;99(5):3182–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Liao Y, Tang YL, Hao W. Ketamine and international regulations. Am J Drug Alcohol Abuse. 2017;43(5):495–504.

    Article  PubMed  Google Scholar 

  61. Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg. 1966;45(1):29–40.

    Article  CAS  PubMed  Google Scholar 

  62. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.

    Article  CAS  PubMed  Google Scholar 

  63. Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82.

    Article  CAS  PubMed  Google Scholar 

  64. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(4):1155–9.

    Article  CAS  Google Scholar 

  65. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155:123–9.

    Article  CAS  PubMed  Google Scholar 

  67. Domino EF. Taming the ketamine tiger—1965. Anesthesiology. 2010;113(3):678–84.

    Article  PubMed  Google Scholar 

  68. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83(1):18–28.

    Article  CAS  PubMed  Google Scholar 

  70. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Zhang JC, Li SX, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–41.

    Article  CAS  PubMed  Google Scholar 

  72. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2018;75(2):139–48.

    Article  Google Scholar 

  73. Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2019;76(9):893–903.

    Article  Google Scholar 

  74. Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–38.

    Article  PubMed  Google Scholar 

  75. Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–30.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–41.

    Article  PubMed  Google Scholar 

  77. Spravato Prescribing Information. Spravato (esketamine) [package insert]. Titusville, NJ: Janssen Pharmaceutical; 2019.

    Google Scholar 

  78. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79(2):565–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Martin D, Lodge D. Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology. 1985;24(10):999–1003.

    Article  CAS  PubMed  Google Scholar 

  80. Yamamura T, Harada K, Okamura A, Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology. 1990;72(4):704–10.

    Article  CAS  PubMed  Google Scholar 

  81. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852–7.

    Article  PubMed  Google Scholar 

  83. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012;62(1):35–41.

    Article  CAS  PubMed  Google Scholar 

  84. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42(4):222–9.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86(4):903–17.

    Article  CAS  PubMed  Google Scholar 

  86. Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317–22.

    Article  CAS  PubMed  Google Scholar 

  87. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27(43):11496–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017;22(1):120–6.

    Article  CAS  PubMed  Google Scholar 

  89. Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. elife. 2014;3:3581.

    Article  Google Scholar 

  90. Ignácio ZM, Réus GZ, Arent CO, Abelaira HM, Pitcher MR, Quevedo J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br J Clin Pharmacol. 2016;82(5):1280–90.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, et al. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. Mol Psychiatry. 2018;23(4):812–23.

    Article  CAS  PubMed  Google Scholar 

  92. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020;45(6):990–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Suzuki K, Monteggia LM. The role of eEF2 kinase in the rapid antidepressant actions of ketamine. Adv Pharmacol. 2020;89:79–99.

    Article  CAS  PubMed  Google Scholar 

  95. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153–5.

    Article  PubMed  Google Scholar 

  96. Yamaguchi JI, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, et al. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology. 2018;43(9):1900–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-Norketamine. Biol Psychiatry. 2018;84(8):591–600.

    Article  CAS  PubMed  Google Scholar 

  98. Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, et al. Synthesis and N-methyl-d-aspartate (NMDA) receptor activity of ketamine metabolites. Org Lett. 2017;19(17):4572–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002;96(2):357–66.

    Article  CAS  PubMed  Google Scholar 

  100. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–55.

    Article  CAS  PubMed  Google Scholar 

  101. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  102. Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. https://doi.org/10.4088/JCP.19m13191.

    Article  PubMed  Google Scholar 

  103. Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31.

    Article  PubMed  Google Scholar 

  104. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Ader R, Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med. 1975;37(4):333–40.

    Article  CAS  PubMed  Google Scholar 

  107. Plaut M. Lymphocyte hormone receptors. Annu Rev Immunol. 1987;5:621–69.

    Article  CAS  PubMed  Google Scholar 

  108. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2(4):269–76.

    Article  CAS  PubMed  Google Scholar 

  109. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15(3):199–226.

    Article  CAS  PubMed  Google Scholar 

  110. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci. 2003;100(4):1920–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630–3.

    Article  PubMed  Google Scholar 

  112. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  113. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry. 2008;63(11):1022–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.

    Article  CAS  PubMed  Google Scholar 

  115. Kopra E, Mondelli V, Pariante C, Nikkheslat N. Ketamine’s effect on inflammation and kynurenine pathway in depression: a systematic review. J Psychopharmacol. 2021;35(8):934–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest. 2012;122(8):2940–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Dobos N, de Vries EF, Kema IP, Patas K, Prins M, Nijholt IM, et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis. 2012;28(4):905–15.

    Article  CAS  PubMed  Google Scholar 

  118. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988–1000.

    Article  PubMed  Google Scholar 

  119. Borland LM, Michael AC. Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem. 2004;91(1):220–9.

    Article  CAS  PubMed  Google Scholar 

  120. Myint AM, Schwarz MJ, Müller N. The role of the kynurenine metabolism in major depression. J Neural Transm. 2012;119(2):245–51.

    Article  CAS  PubMed  Google Scholar 

  121. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72(4):411–2.

    Article  CAS  PubMed  Google Scholar 

  122. Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun. 2013;28:170–81.

    Article  CAS  PubMed  Google Scholar 

  123. Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997;247(4):228–33.

    Article  CAS  PubMed  Google Scholar 

  124. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. Illness, cytokines, and depression. Ann N Y Acad Sci. 2000;917:478–87.

    Article  CAS  PubMed  Google Scholar 

  125. Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry. 2013;18(10):1119–24.

    Article  CAS  PubMed  Google Scholar 

  126. Jia Y, Liu L, Sheng C, Cheng Z, Cui L, Li M, et al. Increased serum levels of cortisol and inflammatory cytokines in people with depression. J Nerv Ment Dis. 2019;207(4):271–6.

    Article  PubMed  Google Scholar 

  127. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.

    Article  PubMed  Google Scholar 

  128. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–11.

    Article  CAS  PubMed  Google Scholar 

  129. Krause D, Myint AM, Schuett C, Musil R, Dehning S, Cerovecki A, et al. High Kynurenine (a tryptophan metabolite) predicts remission in patients with major depression to add-on treatment with Celecoxib. Front Psych. 2017;8:16.

    Google Scholar 

  130. Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord. 2020;261:145–52.

    Article  CAS  PubMed  Google Scholar 

  131. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology. 1998;37(2):93–7.

    Article  CAS  PubMed  Google Scholar 

  132. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.

    Article  CAS  PubMed  Google Scholar 

  133. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65(4):296–303.

    Article  CAS  PubMed  Google Scholar 

  134. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(2):201–17.

    Article  CAS  Google Scholar 

  135. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43(4):425–73.

    CAS  PubMed  Google Scholar 

  136. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49(5):391–404.

    Article  CAS  PubMed  Google Scholar 

  137. Claes SJ. CRH, stress, and major depression: a psychobiological interplay. Vitam Horm. 2004;69:117–50.

    Article  CAS  PubMed  Google Scholar 

  138. Holsboer F, Ising M. Central CRH system in depression and anxiety—evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583(2–3):350–7.

    Article  CAS  PubMed  Google Scholar 

  139. Musazzi L, Racagni G, Popoli M. Stress, glucocorticoids and glutamate release: effects of antidepressant drugs. Neurochem Int. 2011;59(2):138–49.

    Article  CAS  PubMed  Google Scholar 

  140. van Tol MJ, van der Wee NJ, van den Heuvel OA, Nielen MM, Demenescu LR, Aleman A, et al. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry. 2010;67(10):1002–11.

    Article  PubMed  Google Scholar 

  141. Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011;62(1):47–58.

    CAS  PubMed  Google Scholar 

  142. Van der Linden P, Gilbart E, Engelman E, Schmartz D, de Rood M, Vincent JL. Comparison of halothane, isoflurane, alfentanil, and ketamine in experimental septic shock. Anesth Analg. 1990;70(6):608–17.

    PubMed  Google Scholar 

  143. Yli-Hankala A, Kirvelä M, Randell T, Lindgren L. Ketamine anaesthesia in a patient with septic shock. Acta Anaesthesiol Scand. 1992;36(5):483–5.

    Article  CAS  PubMed  Google Scholar 

  144. Lange M, Bröking K, van Aken H, Hucklenbruch C, Bone HG, Westphal M. Role of ketamine in sepsis and systemic inflammatory response syndrome. Anaesthesist. 2006;55(8):883–91.

    Article  CAS  PubMed  Google Scholar 

  145. Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res. 2018;269:207–11.

    Article  CAS  PubMed  Google Scholar 

  146. Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017;7(3):1065.

    Article  Google Scholar 

  147. Dale O, Somoyogi AA, Yiba L, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg. 2012;115(4):934–43.

    Article  CAS  PubMed  Google Scholar 

  148. Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018;95:43–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Zhang GF, Wang J, Han JF, Guo J, Xie ZM, Pan W, et al. Acute single dose of ketamine relieves mechanical allodynia and consequent depression-like behaviors in a rat model. Neurosci Lett. 2016;631:7–12.

    Article  CAS  PubMed  Google Scholar 

  150. Verdonk F, Petit AC, Abdel-Ahad P, Vinckier F, Jouvion G, de Maricourt P, et al. Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. Brain Behav Immun. 2019;81:361–73.

    Article  CAS  PubMed  Google Scholar 

  151. Wang W, Liu L, Yang X, Gao H, Tang QK, Yin LY, et al. Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice. Behav Brain Res. 2019;364:75–84.

    Article  CAS  PubMed  Google Scholar 

  152. Johnston CJ, Fitzgerald PJ, Gewarges JS, Watson BO, Spencer-Segal JL. Ketamine decreases HPA axis reactivity to a novel stressor in male but not female mice. bioRxiv. 2021.

    Google Scholar 

  153. Walker AJ, Foley BM, Sutor SL, McGillivray JA, Frye MA, Tye SJ. Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Behav Brain Res. 2015;293:198–202.

    Article  CAS  PubMed  Google Scholar 

  154. Rong C, Park C, Rosenblat JD, Subramaniapillai M, Zuckerman H, Fus D, et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health. 2018;15(4):771.

    Article  PubMed  PubMed Central  Google Scholar 

  155. National Institute of Health. Clinicaltrials.gov: treatment resistant depression [Internet]. 2021. Clinicaltrials.gov.

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Loyola University Stritch School of Medicine, Maywood, IL, USA

    Angelos Halaris & John Cook

Authors
  1. Angelos Halaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelos Halaris .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Korea University Ansan Hospital, Ansan, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Halaris, A., Cook, J. (2023). The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?. In: Kim, YK. (eds) Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders. Advances in Experimental Medicine and Biology, vol 1411. Springer, Singapore. https://doi.org/10.1007/978-981-19-7376-5_21

Download citation

Publish with us

Policies and ethics

Search

Navigation